에임메드

비상장계속사업자

AIMMED

이영준

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

에임메드

Business Reg. No. 2148639734 · CEO 이영준

I.Investment Overview

Target에임메드 (2148639734)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명에임메드
영문명AIMMED
대표자이영준
사업자등록번호2148639734
법인등록번호1101111787386
설립일1999.10.12
종업원수99명

V.Workforce

99

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW226.62021259.22022281.92023249.92024281.72025
영업이익100M KRW0.12021-26.920222.420235.420245.62025
순이익100M KRW1.52021-31.22022120236.920245.52025
Item20252024202320222021
자산총계433.7억원461.8억원439.9억원452.5억원451.9억원
부채총계172.9억원206.9억원191.9억원206.2억원199.8억원
자본총계260.8억원254.9억원248억원246.3억원252.1억원
매출액281.7억원249.9억원281.9억원259.2억원226.6억원
영업이익5.6억원5.4억원2.4억원-26.9억원1,074만원
순이익5.5억원6.9억원1억원-31.2억원1.5억원

VII.Financial Ratios

FY2025 basis

2%

영업이익률

1.93%

순이익률

1.26%

ROA

2.09%

ROE

66.31%

부채비율

60.13%

자기자본비율

VIII.R&D Activity

Fields 보건의료 > 의료기기·S/W 안전관리 · 정보/통신 > 소프트웨어 · 보건의료 > 의료기기

Keywords 불면증, 음성인식, 인지재활, 치매, 시선추적

YearProjectsPapersPatents
2024100
2023301
2022202
2021314
2020302
2019203
2018102
2017100
2016001
2015100
2013100

IX.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

에임메드 투심보고서 | Alpha Lenz